In glioblastoma cells, low NQO1 activity is a potential mechanism of acquired resistance to 17-AAG, and such resistance can be overcome with another HSP90 inhibitor (VER-50589 or NVP-AUY922) [260]. This evidence concerns the gene HSP90AA1 and glioblastoma.